| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $23,401 | 1 | 7 |
Sells | $33,075 | 13 | 93 |
| Reid Laurence | director | 1 | $23,401 | 0 | $0 | $23,401 |
| Wein Matthew | See Remarks | 0 | $0 | 4 | $2,263 | $-2,263 |
| Thomas Brian C. | director | 0 | $0 | 1 | $6,786 | $-6,786 |
| Wapnick Pamela | Chief Financial Officer | 0 | $0 | 4 | $11,282 | $-11,282 |
| Irish Jian | Chief Executive Officer | 0 | $0 | 4 | $12,743 | $-12,743 |
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with …
Over the last 12 months, insiders at Metagenomi, Inc. Common Stock have bought $23,401 and sold $33,075 worth of Metagenomi, Inc. Common Stock stock.
On average, over the past 5 years, insiders at Metagenomi, Inc. Common Stock have bought $23,401 and sold $43,203 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Reid Laurence (director) — $23,401.
The last purchase of 20,000 shares for transaction amount of $23,401 was made by Reid Laurence (director) on 2026‑09‑09.
| 2026-09-09 | Reid Laurence | director | 20,000 0.0541% | $1.17 | $23,401 | -11.30% | ||
| 2026-09-08 | Sale | Irish Jian | See Remarks | 2,140 0.0057% | $1.16 | $2,479 | -12.07% | |
| 2026-09-08 | Sale | Wapnick Pamela | Chief Financial Officer | 1,911 0.0051% | $1.16 | $2,214 | -12.07% | |
| 2026-09-08 | Sale | Wein Matthew | See Remarks | 358 0.0009% | $1.16 | $415 | -12.07% | |
| 2026-06-05 | Sale | Irish Jian | See Remarks | 3,737 0.0101% | $1.30 | $4,854 | -7.03% | |
| 2026-06-05 | Sale | Wapnick Pamela | Chief Financial Officer | 2,884 0.0078% | $1.30 | $3,746 | -7.03% | |
| 2026-06-05 | Sale | Wein Matthew | See Remarks | 558 0.0015% | $1.30 | $725 | -7.03% | |
| 2026-03-05 | Sale | Irish Jian | Chief Executive Officer | 1,607 0.0043% | $1.60 | $2,571 | -23.60% | |
| 2026-03-05 | Sale | Wapnick Pamela | Chief Financial Officer | 1,581 0.0042% | $1.60 | $2,530 | -23.60% | |
| 2026-03-05 | Sale | Wein Matthew | See Remarks | 482 0.0013% | $1.60 | $771 | -23.60% | |
| 2025-12-05 | Sale | Thomas Brian C. | director | 3,830 0.0103% | $1.77 | $6,786 | -25.28% | |
| 2025-12-05 | Sale | Irish Jian | Chief Executive Officer | 1,602 0.0043% | $1.77 | $2,839 | -25.28% | |
| 2025-12-05 | Sale | Wapnick Pamela | Chief Financial Officer | 1,576 0.0042% | $1.77 | $2,793 | -25.28% | |
| 2025-12-05 | Sale | Wein Matthew | See Remarks | 199 0.0005% | $1.77 | $353 | -25.28% | |
| 2025-09-05 | Sale | Thomas Brian C. | director | 2,701 0.0074% | $1.81 | $4,889 | -22.51% | |
| 2025-09-05 | Sale | Irish Jian | Chief Executive Officer | 1,602 0.0044% | $1.81 | $2,900 | -22.51% | |
| 2025-09-05 | Sale | Wapnick Pamela | Chief Financial Officer | 1,576 0.0043% | $1.81 | $2,853 | -22.51% | |
| 2025-09-05 | Sale | Wein Matthew | See Remarks | 199 0.0005% | $1.81 | $360 | -22.51% | |
| 2025-06-06 | Sale | Thomas Brian C. | Chief Executive Officer | 10,785 0.0286% | $1.75 | $18,874 | -3.47% | |
| 2025-06-06 | Sale | Irish Jian | See Remarks | 6,390 0.0169% | $1.75 | $11,183 | -3.47% |
| Increased Positions | 26 | +35.14% | 2M | +32.02% |
| Decreased Positions | 29 | -39.19% | 829,461 | -13.06% |
| New Positions | 11 | New | 394,110 | New |
| Sold Out Positions | 10 | Sold Out | 419,778 | Sold Out |
| Total Postitions | 71 | -4.05% | 8M | +18.96% |